Description

The Karnofsky Performance Index (KPI-11), also known as the Karnofsky Performance Status (KPS), is one of the most widely used and scientifically established clinician-rated instruments for assessing the functional status and physical performance of patients with chronic, severe, or life-threatening illnesses. Developed in 1949 by David A. Karnofsky and Joseph H. Burchenal, the scale was originally designed to evaluate the functional capacity of patients receiving anticancer therapy. Today, it is extensively used in oncology, palliative care, geriatrics, neurology, rehabilitation medicine, and numerous other medical specialties.

The KPI-11 is completed by a healthcare professional and focuses primarily on assessing a patient’s physical functioning, ability to perform daily activities, and degree of independence. Unlike broader quality-of-life instruments, it does not directly evaluate psychological, cognitive, emotional, or social functioning.

Because of its simplicity, reliability, and strong prognostic value, the Karnofsky Performance Index is widely employed to assess disease progression, determine treatment eligibility, estimate prognosis, monitor therapeutic outcomes, and support clinical decision-making in routine practice and research.

Data Analysis and Applications

Data collected using the KPI-11 are analyzed using established psychometric and statistical methods to evaluate patients’ functional performance and overall clinical status.

The instrument consists of 11 predefined performance levels, ranging from 100 to 0 in 10-point increments. Each level represents a specific degree of independence and functional ability. According to the original scoring guidelines, intermediate values between the predefined categories should not be assigned.

Psychometric evaluation of the KPI-11 typically includes:

  • Internal consistency, assessed using Cronbach’s alpha coefficient.
  • Inter-rater reliability, evaluating agreement among healthcare professionals.
  • Test–retest reliability, assessing score stability over repeated evaluations.
  • Content validity, criterion validity, and convergent validity, established through comparisons with instruments such as the ECOG Performance Status, Barthel Index, SF-36, EQ-5D, and other measures of physical functioning and quality of life.

In clinical and research settings, KPI-11 scores are commonly analyzed using:

  • Descriptive statistics, including means, standard deviations, medians, and frequency distributions.
  • Comparative analyses, such as independent-samples t-tests, Analysis of Variance (ANOVA), Mann–Whitney U tests, and Kruskal–Wallis tests, to compare functional performance across patient groups.
  • Correlation analyses, using Pearson and Spearman correlation coefficients to examine relationships between functional status, survival, symptom burden, and quality of life.
  • Multivariate statistical techniques, including linear regression, logistic regression, Cox proportional hazards regression, mediation and moderation analyses, and Structural Equation Modeling (SEM) to investigate predictors of functional decline, treatment outcomes, and survival.

Purpose

The primary purpose of the Karnofsky Performance Index (KPI-11) is to provide a standardized and objective assessment of a patient’s physical functioning and degree of independence in daily activities.

More specifically, the instrument is designed to:

  • evaluate baseline functional performance before treatment;
  • monitor disease progression over time;
  • assess patients’ response to medical or surgical interventions;
  • estimate prognosis and survival;
  • support clinical decision-making and treatment planning;
  • determine eligibility for clinical trials;
  • facilitate outcome assessment in clinical and epidemiological research.

The KPI-11 provides clinicians with a rapid overview of a patient’s physical condition without directly assessing psychosocial or emotional well-being.

Scoring

The KPI-11 consists of 11 predefined performance categories with scores of:

100, 90, 80, 70, 60, 50, 40, 30, 20, 10, and 0.

The assessment is performed exclusively by a physician or another qualified healthcare professional, based on clinical evaluation.

The scoring system is generally interpreted as follows:

  • 100: Normal activity with no evidence of disease or functional limitations.
  • 80–90: Minor symptoms with preserved independence and ability to perform normal activities.
  • 50–70: The patient is unable to perform normal work and requires varying degrees of assistance with daily activities.
  • 10–40: Severe disability, requiring considerable medical care and continuous assistance.
  • 0: Death.

Higher scores indicate better physical functioning, greater independence, and higher quality of life, whereas lower scores reflect greater functional impairment, increased dependency, and poorer clinical prognosis.

The Karnofsky Performance Index has demonstrated satisfactory psychometric properties and has long been recognized as a reliable indicator of patients’ functional status. According to the available validation data, the reported Cronbach’s alpha coefficient is 0.720, supporting acceptable internal consistency.

References

  • Karnofsky, D. A., & Burchenal, J. H. (1949). The Clinical Evaluation of Chemotherapeutic Agents. In C. M. MacLeod (Ed.), Evaluation of Chemotherapeutic Agents (pp. 191–205). Columbia University Press.
  • Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984). Karnofsky Performance Status Revisited: Reliability, Validity, and Guidelines. Journal of Clinical Oncology, 2(3), 187–193.
  • Mor, V., Laliberte, L., Morris, J. N., & Wiemann, M. (1984). The Karnofsky Performance Status Scale: An Examination of Its Reliability and Validity in a Research Setting. Cancer, 53(9), 2002–2007.
  • Crooks, V., Waller, S., Smith, T., & Hahn, T. J. (1991). The Use of the Karnofsky Performance Scale in Determining Outcomes and Risk in Geriatric Outpatients. Journal of Gerontology, 46(4), M139–M144.